THE A2 MILK COMPANY PRESENTS INFANT FORMULA, DIGESTIVE HEALTH RESEARCH AT NUTRITION 2026

KUALA LUMPUR, July 29 (Bernama) — The a2 Milk Company, a dairy nutrition company, has announced new clinical and preclinical research examining infant growth and safety, protein utilisation and gastrointestinal biomarkers, and digestive tolerance associated with A1- and A2-type beta-casein proteins.

Presented at NUTRITION 2026, the annual meeting of the American Society for Nutrition, the research included studies conducted by The a2 Milk Company as well as company-funded research by investigators from Purdue University and Nova Southeastern University.

The company presented results from a randomised, double-blind controlled trial evaluating infant formula made with milk free from A1-type beta-casein protein (A1PF) in healthy term infants.

The Growth Monitoring Study, which was required by the United States Food and Drug Administration (FDA) for new infant formulas, found that infants fed the A1PF formula experienced normal growth throughout the 16-week study period, meeting the FDA’s predefined non-inferiority criteria compared with a commercially available infant formula.

Additional analyses showed that infants receiving the A1PF formula recorded about six per cent greater average weight gain, around 6.6 per cent greater length gain, and higher weight-for-age and length-for-age z-scores at 16 weeks.

A separate preclinical study presented by The a2 Milk Company Senior Global Research Manager, Kirsty Armstrong, examined the protein component of A1PF infant formula using the Association of Official Analytical Collaboration (AOAC INTERNATIONAL) Protein Efficiency Ratio (PER) Official Method 960.48.

Key findings included higher adjusted PER, elevated antioxidant status, reduced gastrointestinal inflammatory markers, improved intestinal barrier function markers, and increased lactase gene and protein expression.

The company said the findings suggest that A1PF milk in infant formula may support improved protein quality and a more favourable gastrointestinal environment for nutrient utilisation, although further research is needed to determine the clinical significance of these findings.

Researchers from Purdue University also investigated the role of A1- and A2-type beta-casein in digestion and metabolism, while Nova Southeastern University examined how naturally occurring differences in milk proteins may influence inflammation in the gut and brain, contributing to ongoing research into the links between nutrition, inflammation, digestive health and cognitive function.

— BERNAMA

​From Ancient Delicacy to Global Trend: The Industrial Upgrade and Global Journey of Ningxia Goji Berries

Table

Ningxia Goji Berries

ZHONGWEI, China, June 16, 2026 /Xinhua-AsiaNet/–

Lush plantations glitter across the sun-drenched Yellow River alluvial plain at an elevation of 1,100 meters on the eastern flank of the Helan Mountains. This is Zhongning County in the Ningxia Hui Autonomous Region, located in northwestern China. As the opening ceremony of the 9th Goji Berry Industry Expo officially kicks off here, farmers are busy harvesting the first goji berries of 2026.

While goji berries are widely cultivated across China, Ningxia goji berries stand out for their exceptional quality and have become the region’s most iconic specialty. As the core producing area of authentic Ningxia goji berries, also known as wolfberries, Zhongning enjoys over 3,000 hours of annual sunlight. The weakly alkaline soil, formed by the convergence of the Yellow River and Qingshui River, is rich in essential minerals and trace elements. These unique natural conditions have given birth to this distinctive “Magic Fruit.”

“Every single goji berry is hand-picked,” said Pan Tai’an, chairman of Ningxia Wolfberry Goji Industry Co., Ltd., a leading regional goji producer. “The goji trees blossom and bear fruit simultaneously, which means all berries must be harvested manually.”

“Thanks to Ningxia’s cool climate, pests and diseases are rare here. Still, we never use chemical fertilizers or pesticides. We only apply organic compost to guarantee the pure, natural quality of our goji berries,” he added.

From a Local Specialty to a Health and Lifestyle Trend

In China, Ningxia goji berries have been treasured as a medicinal and edible delicacy. It is the only goji variety officially listed for medicinal use in the Pharmacopoeia of the People’s Republic of China. The ancient Chinese medical masterpiece, the Shennong Ben Cao Jing (Classic of Materia Medica), documents their anti-aging properties. This profound cultural heritage has laid a solid foundation for Ningxia goji berries to enter international markets.

Today, this ancient red berry has gained unprecedented global popularity. Boasting powerful anti-aging benefits, high vitamin C content, and abundant antioxidants, Ningxia goji berries have become a trending “superfood” on international social media. Overseas consumers are willing to pay a premium for authentic Ningxia products, freeing the berry from its former identity as a niche, rustic specialty.

“Western researchers have long been studying the health benefits of goji berries, including immune enhancement, anti-tumor effects, and anti-aging properties. They call it a ‘superfood’ and extract its active ingredients for use in health supplements and cosmetics,” Pan Tai’an explains. “This inspired me to focus on deep processing, because that’s where the real value lies.”

For decades, the industry was held back by two major bottlenecks: the extreme perishability of fresh berries and underdeveloped deep-processing technology. To address these issues, the company invested six years in intensive R&D and successfully developed ambient-temperature preservation technology for goji puree. This pioneering breakthrough fills a technical gap and sets world-leading standards for the global goji industry.

To retain precious nutrients, fresh goji berries go through cleaning, pulping, sterilization and canning within two hours after harvest. This rigorous workflow best preserves key nutrients including goji polysaccharides, betaine and zeaxanthin to the greatest extent possible.

Powered by this core innovation, the company has produced over 100,000 tons of goji puree, with total sales exceeding 2 billion yuan (about 293 million U.S. dollars). More importantly, the technology has driven the construction of 50 high-standard production lines across Ningxia, marking a decisive shift – transforming the regional industry from raw material sales to high-value product manufacturing.

According to the latest data provided by the Goji Industry Development Center of the Ningxia Forestry and Grassland Administration, Ningxia’s goji marketing network covers more than 50 countries and regions spanning Southeast Asia, Europe, and the Americas. In 2025, Ningxia’s fresh goji berry output reached 200,000 tons, with the full industrial chain output value exceeding 21.3 billion yuan.

From Product Upgrade to a Global Cultural Brand

While technology-driven companies like Ningxia Wolfberry are deepening their presence in international supply chains, emerging players in the goji industry are reshaping the consumer perception of goji berries as “just a traditional medicinal herb.” As a leader in e-commerce, Ningxia Qilixiang Goji Co., Ltd. is dedicated to promoting this traditional tonic to the younger generation. Founded in 2009 by three university students with a startup fund of just 700 yuan from their living allowances, the company has now grown into a top-tier brand with annual sales exceeding 1 billion yuan.

To transform traditional wellness into a trendy lifestyle, Qilixiang has developed a variety of blended purees – such as goji-ginseng, red date-goji, and mulberry-goji – all paired with eye-catching packaging. Operating about 200 online stores, the company has consistently ranked first in e-commerce sales for goji products.

These Innovative, high-value-added products derived from goji berries – including goji puree, goji seed oil, and goji juice – are now enjoying immense global demand. Once viewed as a mysterious Chinese herbal remedy, Ningxia goji berries have now become part of daily life for middle-class families from New York to London, a favorite among Hollywood celebrities, and a common ingredient in premium restaurants worldwide.

The international reputation is built on rigorous quality control. To meet the highest global food safety standards for organic products, Ningxia goji companies adhere to the world’s most stringent regulations. For instance, Ningxia Wolfberry has held organic certifications from North America, the European Union and Japan for 21 consecutive years, earning a “green pass” to the global market. To date, its products have been exported to 33 countries and regions worldwide.

Today, Ningxia’s goji industry is no longer confined to production and sales; it is gradually embracing a diversified development model. With the establishment of goji art galleries, history museums, and experience centers, the industry is shifting from merely “selling products” to “selling scenery” and “selling culture,” growing into a multi-faceted and integrated economic driver.

The transformation of Ningxia goji berries reflects the progress and the rise of Chinese products and brands. It has evolved from a little-known northwest specialty and low-end raw material exporter into a global health trend and a modern, diversified industry fueled by technology, creativity, and culture. This journey mirrors the broader transformation of China’s traditional agriculture and the innovative drive of its real economy.

Source: Goji Industry Development Center of the Ningxia Forestry and Grassland Administration

EAACI CHAMPIONS VISION ZERO TO REDUCE ALLERGY, ASTHMA BURDEN

KUALA LUMPUR, June 12 (Bernama) — The European Academy of Allergy and Clinical Immunology (EAACI) is calling for a new global health ambition through Vision Zero, a future free from the burden of allergy and asthma.

As allergic diseases continue to affect hundreds of millions of people worldwide and place growing pressure on healthcare systems, this vision will serve as the central theme of the four-day EAACI Annual Congress 2026 in Istanbul, Türkiye, beginning June 12.

The congress will bring together thousands of clinicians, researchers and healthcare professionals to discuss the latest scientific advances and the future of allergy and asthma care, according to EAACI in a statement.

“Vision Zero reflects our determination to move beyond disease management and towards disease prevention and burden reduction. Through collaboration across research, clinical practice and public health, we can work towards a future where allergy and asthma no longer limit the lives of millions,” said EAACI President, María Torres.

EAACI believes scientific innovation, prevention strategies and coordinated policy action can significantly reduce the impact of allergic and respiratory diseases on individuals, families and societies rather than accepting them as an inevitable and growing public health challenge.

The congress will showcase emerging research and clinical developments in immunotherapy, environmental and genetic factors, digital health technologies, precision medicine and preventive approaches. Discussions will also address health equity and the need to ensure that advances in allergy and asthma care are accessible to patients worldwide.

Allergic diseases are among the most common chronic conditions globally, and their burden extends beyond healthcare to affect education, productivity, quality of life and mental wellbeing.

Against this backdrop, EAACI’s Vision Zero initiative seeks to encourage long-term thinking about what is possible when scientific discovery is matched by effective implementation and policy support. The congress is expected to bring together experts worldwide to accelerate progress towards substantially reducing the burden of allergy and asthma.

— BERNAMA

Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial

  • MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo
  • Improvements observed across key symptoms, including nausea, early satiety, post-prandial fullness and upper abdominal pain
  • Favorable safety and tolerability profiles
  • Late-breaking oral presentation delivered at Digestive Disease Week (DDW) 2026 in Chicago, IL

FREIBURG, Germany and ROSCREA, Ireland, May 5 (Bernama-GLOBE NEWSWIRE) — Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage biopharmaceutical company, today announced positive results from MOVE-IT (NCT05621811), a global Phase 2b, randomized placebo-controlled trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesis. 

The double-blind, multicenter, 12-week study enrolled 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis symptoms and objective evidence of delayed gastric emptying. Eligible patients received either 10 mg, 20 mg, 40 mg naronapride, or placebo, administered orally three times a day (TID) for 12 weeks.  

MOVE-IT met the primary endpoint, demonstrating statistically significant improvement versus placebo in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Core Symptom Score in the 20 mg TID (p=0.0046) and 40 mg TID (p=0.0156) groups. The ANMS GCSI-DD is a content-validated, patient-reported outcome instrument that assesses the five cardinal gastroparesis symptoms: nausea, vomiting, early satiety, postprandial fullness and upper abdominal pain.

Table 1. Primary endpoint – Change from baseline to Week 12 in the average weekly ANMS GCSI-DD Core Symptom Score

  Naronapride 
10 mg TID
Naronapride
20 mg TID
Naronapride
40 mg TID
Placebo
TID
Total PopulationN=83N=80N=80  N=85
Baseline (BSL)

Week 12
 Mean (SD)

Mean (SD)
 2.450 (0.388)

1.155 (0.797)
 2.429 (0.341)

0.883 (0.759)
 2.462 (0.450)

0.907 (0.780)
 2.402 (0.396)

1.280 (0.911)
Change to Week 12 LS Mean (SE)
 +/- 95% CI
  -1.244 (0.100)
 [-1.440, -1.048]
  -1.512 (0.102)
 [-1.712, -1.311]
 -1.452 (0.100)
 [-1.649, -1.256]
 -1.106 (0.095)
 [-1.293, -0.920]
Difference to
Placebo
 LS Mean (SE) -0.138 (0.136) -0.405 (0.137) -0.346 (0.136) 
Dunnett-Hsu
Adjusted
 97.5%-CI
 p-value†
 [-∞, 0.183]
 0.3112
 [-∞, -0.081]
 0.0046
 [-∞, -0.024]
 0.0156
 

CI = Confidence interval; LS Means = Least square means; N = Number of participants in analysis population; SD = Standard deviation; SE = Standard error. † One-sided

Naronapride also demonstrated statistically significant improvements versus placebo from baseline to Week 12 across key secondary and exploratory endpoints in the total population:

  • ANMS GCSI-DD Composite Score (core score excluding vomiting): Statistically significant improvements observed in 20 mg (p=0.0024) and 40 mg (p=0.0117) TID dose groups versus placebo.
  • Responder Analyses: Approximately 15-20% more participants achieved clinically meaningful improvement (defined as >1.0 decrease in ANMS GCSI-DD Composite Score) with naronapride 20 mg or 40 mg TID vs. placebo, with no added benefit of 40 mg over 20 mg.  
  • Patient-Reported Quality of Life (QoL): Global improvements reflecting meaningful benefit beyond core symptom reduction and supporting consistency of treatment effect across validated symptom assessment instruments.
  • Improvement in gastric emptying breath test (GEBT): All active doses achieved greater gastric emptying versus placebo. Maximum improvement with 20 mg (mean -21.95 minutes) and 40 mg (mean –14.92 minutes) versus placebo (mean –10.96 minutes).

Consistent with previous studies, the safety and tolerability profiles were favorable, with no new safety signals identified versus placebo, including cardiac, neuropsychiatric, or prolactin-related signals. To date, naronapride has been studied in over 1200 subjects, with a safety profile reflecting its minimal systemic absorption. 

Dr. Kai Pinkernell, M.D., Managing Director Science & Innovation at Dr. Falk Pharma, commented: “We are excited about the outcomes showing a significant and clinically meaningful impact on gastroparesis symptoms, all combined with a favorable safety profile. This is an important step towards providing physicians and patients with a treatment option where few effective choices exist. We look forward to sharing these results with the scientific community, engaging with regulatory authorities, and moving decisively toward registration studies later this year and eventual commercialization.” 

Dr. Peter Milner, M.D., FACC, Chairman and CEO of Renexxion, commented: “These Phase 2b results represent a significant milestone for the naronapride program, demonstrating statistically significant improvement in gastroparesis symptoms with a favorable safety and tolerability profile. We believe naronapride’s locally acting, dual mechanism pharmacology and safety-by-design profile position it as a potential best-in-class therapy for gastroparesis, a disease with significant unmet medical need and limited, safe, effective long-term treatment options. Together with our partner Dr. Falk Pharma, we are now focused on advancing naronapride into late-stage development with the goal of bringing an important new treatment option to physicians and patients.”

About Naronapride
Naronapride is a potential best-in-class oral, locally acting pan-GI prokinetic designed to enhance coordinated motility across the digestive tract. Naronapride works through a differentiated dual mechanism of action- 5-HT4 receptor agonism and dopamine D2 receptor antagonism- modulating two validated targets on the luminal surface of the intestinal wall that regulate GI motility and nausea signaling.  Naronapride’s dual pharmacology, minimal systemic bioavailability, and differentiated pharmaceutical and pharmacokinetic profile are designed to deliver targeted activity within the GI tract while limiting systemic exposure. To date, naronapride has demonstrated a favorable safety and tolerability profile across nine Phase 1 clinical trials and five Phase 2 clinical trials conducted in multiple indications including gastroesophageal reflux disease, erosive esophagitis and chronic idiopathic constipation.

About Gastroparesis
Gastroparesis is a chronic gastrointestinal disorder characterized by delayed gastric emptying and debilitating symptoms including nausea, vomiting, early satiety, upper abdominal pain and postprandial fullness. Approximately 22 per 100,000 individuals across US and Europe are formally diagnosed with gastroparesis, while up to 12-times more experience symptoms consistent with the disease. Despite the substantial disease burden, the availability of safe and effective long‑term treatment options remains limited.

About Renexxion
Renexxion Ireland Limited, a wholly-owned Irish subsidiary of California-based Renexxion, Inc., is a privately held biopharmaceutical company committed to developing new therapies for patients with gastrointestinal disorders. Renexxion’s lead program is naronapride, a late-stage drug candidate being developed for multiple unmet indications in the upper and lower GI tract.

Further information on Renexxion can be found online: https://www.rnexltd.ie

Media Inquiries:   
Press@rnexltd.ie
+353 61 539121

About Dr. Falk Pharma GmbH  
Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy, and Switzerland. Falk employs approximately 1,550 individuals globally and 450 in Freiburg.

Further information on Dr. Falk Pharma can be found online: https://drfalkpharma.com

SOURCE: Dr. Falk Pharma